Latest filing published 17 Jul 2026 for Catalyst Pharmaceuticals, INC., €395k.
Jeffrey Del Carmen (senior executive) discloses dealings in Catalyst Pharmaceuticals, Inc. to SEC (Form 4). The record holds 41 filings, for trades running from 24 June 2021 to 15 July 2026.
The open-market record consists of 10 sales worth €4.6M, with no purchase. Besides market trades, the filings include 12 share grants and 18 option exercises.
On 17 July 2026 came the latest disclosure, a transaction for €395k in Catalyst Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations